Jiangsu Pacific minok bio Pharmaceutical Co., Ltd
EN CN
 
  • Meplazumab was approved for phase II/III clinical trials for the treatment of COVID-19 pneumonia by US FDA on November 13, 2020.
  • November 13,2020




  • PREVIOUS：PMBP's orphan-drug designat...
  • NEXT：Meplazumab was approved for pha...
    •  
  • COMPANY
  • About us
  • Vision
  • Mission
  • History
  • Team
  • News and events
  • News and events
  • Meet us
  • SCIENCE & RESEARCH
  • New target
  • Oncology
  • Infectious diseases
  • Research collaborations
  • Clinical trial capabilities
  • Our pipeline
  • Science & research
  • Expanded Access
  • CAREER
  • Working with us
  • Job vacancies
  • TECHNOLOGIES
  • Process science
  • Expression system
  • Process development
  • GMP manufacturing
  • Quality Control
  • Quality Management
  • CDMO
  • Business opportunities
  • CONTACT US
  • Location
  • Contact
    		•
    Stay up to date on Pacific Meinuoke
    © Pacific Meinuoke         Legal Notice       苏ICP备10218680号-1